Fulcrum Therapeutics
FULC
122 hedge funds and large institutions have $374M invested in Fulcrum Therapeutics in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 46 reducing their positions, and 19 closing their positions.
874% more call options, than puts
Call options by funds: $6.27M | Put options by funds: $643K
152% more capital invested
Capital invested by funds: $148M → $374M (+$226M)
26% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 19
5.62% more ownership
Funds ownership: 95.16% → 100.78% (+5.6%)
4% more funds holding
Funds holding: 117 → 122 (+5)
26% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.5M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
+$7.16M |
| 3 |
Goldman Sachs
New York
|
+$3.96M |
| 4 |
D.E. Shaw & Co
New York
|
+$3.19M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.86M |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$2.34M |
| 3 |
BlackRock
New York
|
-$1.77M |
| 4 |
Renaissance Technologies
New York
|
-$1.73M |
| 5 |
EAM
Exome Asset Management
New York
|
-$1.31M |
FULC Hedge Fund Activity: Q2 2025 in Review
122 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Fulcrum Therapeutics (FULC) for Q2 2025, worth a combined $374M — up 152% from $148M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FULC positions and 19 closed out — a net gain of 5 holders — while 34 added to existing stakes and 46 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $8.5M. The largest seller was Nantahala Capital Management, cutting an estimated $2.86M.
- 122 institutional investors held Fulcrum Therapeutics (FULC) as of Q2 2025, up from 117 in Q1 2025.
- Funds reported $374M of Fulcrum Therapeutics stock for Q2 2025, up 152% quarter-over-quarter.
- 24 funds opened new Fulcrum Therapeutics positions in Q2 2025 and 19 closed out, a net change of +5 holders.
- The largest Fulcrum Therapeutics buyer in Q2 2025 was Adage Capital Partners, an estimated $8.5M added.
- The largest Fulcrum Therapeutics seller in Q2 2025 was Nantahala Capital Management, an estimated $2.86M sold.
Based on aggregated 13F filings for Q2 2025.